Stryker (SYK) Stock Forecast & Price Target $313.48 -8.01 (-2.49%) Closing price 03:59 PM EasternExtended Trading$313.95 +0.47 (+0.15%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Stryker - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 22 Analyst RatingsSell0Hold6Buy16 Based on 22 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 6 have given a hold rating, and 16 have given a buy rating for SYK. Consensus Price Target $395.4826.16% Upside According to the 22 analysts' twelve-month price targets for Stryker, the average price target is $395.48. The highest price target for SYK is $465.00, while the lowest price target for SYK is $315.00. The average price target represents a forecasted upside of 26.16% from the current price of $313.48. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for SYK and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYK Analyst Ratings Over TimeTypeCurrent Forecast5/21/25 to 5/21/261 Month Ago4/21/25 to 4/21/263 Months Ago2/20/25 to 2/20/261 Year Ago5/21/24 to 5/21/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy16 Buy rating(s)15 Buy rating(s)12 Buy rating(s)15 Buy rating(s)Hold6 Hold rating(s)6 Hold rating(s)4 Hold rating(s)4 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$395.48$421.11$426.94$427.05Forecasted Upside26.16% Upside28.53% Upside12.31% Upside12.37% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy SYK Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History SYK Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Stryker Stock vs. The CompetitionTypeStrykerMedical CompaniesBroader MarketConsensus Rating Score 2.73 2.29 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside23.20% Upside1,725.93% Upside16.45% UpsideNews Sentiment RatingPositive NewsSee Recent SYK NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/4/2026 Weiss RatingsNot Rated DowngradeHold (C+) ➝ Hold (C)5/4/2026 Truist Financial3 of 5 starsRichard Newitter2 of 5 starsReiterated RatingHold$380.00 ➝ $330.00+13.11%5/4/2026 Barclays3 of 5 starsMatt Miksic2 of 5 starsLower TargetOverweight$469.00 ➝ $394.00+33.36%5/1/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid RomanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingNeutral$361.00+22.19%5/1/2026 Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$410.00+35.16%5/1/2026 Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$385.00+27.40%5/1/2026 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$355.00+17.48%5/1/2026 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$315.00+1.65%5/1/2026 Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKyle RoseSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$435.00 ➝ $400.00+35.39%5/1/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRobbie MarcusSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$445.00 ➝ $400.00+33.29% Get the Latest News and Ratings for SYK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter. 5/1/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLarry BiegelsenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$456.00 ➝ $418.00+35.99%5/1/2026 BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRyan ZimmermanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$397.00 ➝ $379.00+20.46%5/1/2026 Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMike MatsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$454.00 ➝ $418.00+32.85%4/13/2026 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMike KratkySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$410.00+20.83%4/7/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoanne WuenschSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$420.00 ➝ $385.00+15.69%3/17/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDanielle AntalffySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$400.00 ➝ $380.00+7.81%3/5/2026 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform3/4/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew TaylorSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$465.00+21.57%1/27/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOverweight1/26/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeBuy ➝ Hold$387.00+8.35%1/6/2026 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeMarket Perform ➝ Outperform$418.00+19.86%12/19/2025 Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid TurkalySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$440.00+24.63%11/14/2025 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingShagun SinghSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$435.00+16.64%9/18/2025 Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$420.00+11.54%5/2/2025 Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJason WittesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$405.00 ➝ $456.00+20.75%2/3/2025 ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid ToungSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$450.00+17.62%1/29/2025 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRick WiseSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$400.00 ➝ $440.00+11.41%12/2/2024 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeEqual Weight ➝ Overweight$370.00 ➝ $445.00+13.48%9/10/2024 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMike PolarkSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$405.00+11.64%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:51 PM ET. Should I Buy Stryker Stock? SYK Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, May 19, 2026. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com. Stryker Bull Case Here are some ways that investors could benefit from investing in Stryker Co.: The current stock price is around $292, which may present a buying opportunity for investors looking for value in the medical technology sector. Stryker Co. has a strong market presence with a market capitalization of approximately $111.88 billion, indicating stability and growth potential. The company reported a quarterly revenue increase of 2.6% compared to the same quarter last year, showcasing its ability to grow even in challenging market conditions. Analysts have a positive outlook, with 16 investment analysts rating the stock as a Buy, suggesting confidence in the company's future performance. Stryker Co. has a solid dividend yield of 1.1%, providing investors with a steady income stream, which is particularly attractive in the current economic climate. Stryker Bear Case Investors should be bearish about investing in Stryker Co. for these reasons: The company recently missed earnings expectations, reporting $2.60 earnings per share (EPS) against a consensus estimate of $2.98, which may raise concerns about its profitability. There has been insider selling, with a vice president selling over 5,000 shares, which could indicate a lack of confidence in the company's short-term prospects. UBS Group has downgraded its price target for Stryker Co. from $400 to $380, reflecting a more cautious outlook from analysts. The stock has experienced volatility, with a 52-week high of $404.87 and a low of $289.91, indicating potential risks for investors looking for stability. The company's debt-to-equity ratio of 0.62 suggests a moderate level of debt, which could be a concern if interest rates rise or if the company faces financial challenges. SYK Forecast - Frequently Asked Questions What is Stryker's forecast for 2026? According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $395.48, with a high forecast of $465.00 and a low forecast of $315.00. Should I buy or sell Stryker stock right now? 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYK shares. Does Stryker's stock price have much upside? According to analysts, Stryker's stock has a predicted upside of 26.16% based on their 12-month stock forecasts. Has Stryker been downgraded by Wall Street analysts recently? Over the previous 90 days, Stryker's stock had 1 downgrade by analysts. What analysts cover Stryker? Stryker has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Robert W. Baird, Sanford C. Bernstein, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, Wells Fargo & Company, and William Blair in the past 90 days. Do Wall Street analysts like Stryker more than its competitors? Analysts like Stryker more than other "medical" companies. The consensus rating for Stryker is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how SYK compares to other companies. Stock Forecasts and Research Tools Related Companies ISRG Stock Forecast BSX Stock Forecast CAH Stock Forecast COR Stock Forecast DVA Stock Forecast MDT Stock Forecast ZBH Stock Forecast ABT Stock Forecast EW Stock Forecast IDXX Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Stryker RecommendationsWall Street ZenWeiss RatingsTruist FinancialBarclaysBTIG ResearchEvercoreNeedham & Company LLCThe Goldman Sachs GroupSanford C. BernsteinWells Fargo & CompanyRobert W. BairdCanaccord Genuity GroupDeutsche Bank AktiengesellschaftJPMorgan Chase & Co.Leerink Partners This page (NYSE:SYK) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stryker Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Stryker With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
